Sun Pharma to acquire Ocular Technologies – Feedback

Sun Pharmaceutical will acquire Ocular Technologies Sarl (OTS) from a portfolio company of Auven Therapeutics, an international private equity company focused on therapeutic drugs.

OTS owns exclusive, worldwide rights to Seciera (cyclosporine A, 0.09% ophthalmic solution). Sun Pharma will pay Auven $40 million upfront and contingent development milestones and sales milestones as well as tiered royalty on sales of Seciera.Seciera is currently in a phase-3 confirmatory clinical trial for the treatment of dry eye disease.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *